A Study of the Pharmacokinetics of Two Formulations of MK-1006 (MK-1006-010 AM1)(COMPLETED)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00979459
First received: September 17, 2009
Last updated: September 10, 2012
Last verified: September 2012
Results First Received: July 12, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Pharmacokinetics Study;   Intervention Model: Crossover Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Type 2 Diabetes
Interventions: Drug: MK-1006 DFC
Drug: MK-1006 FCT

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
MK-1006 DFC, Then MK-1006 FCT Participants received a single dose of four 20 mg MK-1006 dry filled capsules (DFC) followed by a single dose of two 40 mg MK-1006 film coated tablets (FCT) after a 7 day washout period.
MK-1006 FCT, Then MK-1006 DFC Participants received a single dose of two 40 mg film coated tablets (FCT) of MK-1006 followed by a single dose of four 20 mg MK-1006 dry filled capsules (DFC) after a 7 day washout period.

Participant Flow for 3 periods

Period 1:   First Intervention
    MK-1006 DFC, Then MK-1006 FCT     MK-1006 FCT, Then MK-1006 DFC  
STARTED     6     6  
COMPLETED     6     6  
NOT COMPLETED     0     0  

Period 2:   7-day Washout Period
    MK-1006 DFC, Then MK-1006 FCT     MK-1006 FCT, Then MK-1006 DFC  
STARTED     6     6  
COMPLETED     6     6  
NOT COMPLETED     0     0  

Period 3:   Second Intervention
    MK-1006 DFC, Then MK-1006 FCT     MK-1006 FCT, Then MK-1006 DFC  
STARTED     6     6  
COMPLETED     6     6  
NOT COMPLETED     0     0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
All Participants Includes participants who were randomized to receive either a single dose of four 20 mg MK-1006 DFC followed by a single dose of two 40 mg MK-1006 FCT or a single dose of four 20 mg MK-1006 FCT followed by a single dose of two 40 mg MK-1006 DFC

Baseline Measures
    All Participants  
Number of Participants  
[units: participants]
  12  
Age, Customized  
[units: participants]
 
<35 years     0  
Between 35 and 65 years     12  
>65 years     0  
Gender  
[units: participants]
 
Female     5  
Male     7  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Area Under the Concentration Versus Time Curve (AUC(0-infinity)) for MK-1006   [ Time Frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72, 96 and 120 hours post-dose ]

2.  Primary:   Maximum Plasma Concentration (Cmax) for MK-1006   [ Time Frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72, 96 and 120 hours post-dose ]

3.  Secondary:   Number of Participants Who Experienced at Least One Adverse Event   [ Time Frame: Through 30 days post-dose ]

4.  Secondary:   Number of Participants Who Discontinued Study Medication Due to an Adverse Event   [ Time Frame: up to 8 days ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Vice President, Late Stage Development Group Leader
Organization: Merck Sharp & Dohme Corp
phone: 1-800-672-6372
e-mail: ClinicalTrialsDisclosure@merck.com


No publications provided


Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00979459     History of Changes
Other Study ID Numbers: MK-1006-010, 2009_663
Study First Received: September 17, 2009
Results First Received: July 12, 2012
Last Updated: September 10, 2012
Health Authority: United States: Food and Drug Administration